Trial Profile
A Double-blind, Randomized, Placebo-controlled Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of Oral AZD5055 Following Single and Multiple Ascending Doses
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Apr 2023
Price :
$35
*
At a glance
- Drugs AZD 5055 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca
- 21 Apr 2023 Status changed from recruiting to completed.
- 01 Nov 2022 Planned End Date changed from 17 Feb 2023 to 6 Mar 2023.
- 01 Nov 2022 Planned primary completion date changed from 17 Feb 2023 to 6 Mar 2023.